SBS-IF is the second orphan disease target indication for Jaguar’s intestinal failure program, which includes microvillus inclusion disease (MVID) – for which the company completed a meeting in ...
This new IP supports crofelemer’s global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer ...
Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its ...
6d
EDX Medical's New Advanced Bowel Cancer Testing Service to Launch in UK to Improve Early Detection
A new, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinical validity will be available in the UK within the next few weeks. The service ...
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE:AGN) (FRANKFURT: AGW) (OTCB:BTHCF) (the "Company" or "Algernon") a clinical stage pharmaceutical ...
The "Remote Irritable Bowel Syndrome (IBS) Monitoring Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.
Experts have identified for the first time exactly how exercise can lower your risk of getting bowel cancer and slow the growth of tumors. Experts have identified for the first time exactly how ...
GlaxoSmithKline and Adolor Corporation Bowel Drug Linked to Heart Risk; Halting Studies LONDON & EXTON, Pa. - GlaxoSmithKline and Adolor Corporation today announced data from Study 767905/014 and ...
LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “we” or “us”), a biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback